Want to contact a District of Columbia Humira lawyer? ...Get a free case evaluation from one of our District of Columbia Humira lawyers now.
Home : Unsafe Drugs : Humira : MSN Newsfeeds
Humira - MSN Newsfeeds
- eMaxHealth.com - The representative LPMT selected for this trial was HUMIRA (adalimumab), based on the product being readily commercially available, well-recognized, labeled for SC route of administration, and for which a validated assay for PK profiling could be ...
- RTT News - Injection of rHuPH20 with Humira was well tolerated at all rHuPH20 dose levels, without dose-limiting toxicity, premature withdrawals, or serious adverse events. The company noted that rHuPH20 is the first and only hyaluronidase from a recombinant ...
- RTT News - Injection of rHuPH20 with Humira was well tolerated at all rHuPH20 dose levels, without dose-limiting toxicity, premature withdrawals, or serious adverse events. The company noted that rHuPH20 is the first and only hyaluronidase from a recombinant ...
- RTT News - For the primary endpoint of area under the curve for adalimumab plasma concentration, the AUC over the 14 days following administration was higher when the HUMIRA was co-injected with rHuPH20 compared to the HUMIRA injection without rHuPH20 for 100 ...
- Medical News Today - Rheumatoid arthritis (RA) is one of the most common causes of disability in the Western world. New data released today show that rheumatoid arthritis (RA) patients treated with Abbott's HUMIRA(TM) (adalimumab) stayed working longer, had fewer ...
- Motley Fool - Should it receive approval for the treatment of Crohn's disease, Tysabri would face an uphill battle in gaining market share away from established treatments such as Johnson & Johnson 's (NYSE: JNJ ) Remicade and Abbott 's (NYSE: ABT ) Humira. And while ...
- Chicago Sun-Times - Abbott was cited for its PathVysion test for breast cancer patients and its Humira-brand rheumatoid arthritis medicine. White began his career as a management consultant with McKinsey & Co. Joining Abbott in 1984 he quickly rose through the ranks ...
- Medical News Today - Before receiving treatment with ORENCIA individuals should tell their doctor if they are taking a TNF blocker (e.g., Enbrel®, Humira®, Remicade®) to treat rheumatoid arthritis (RA). ORENCIA® (abatacept) should not be taken with these medications ...
- St. Petersburg Times - He cites the case of Humira, Abbott Laboratories' blockbuster drug for inflammatory diseases developed partly from Lerner's research. Thousands of people with rheumatoid arthritis take Humira, which is injected twice a month. Doctors and patients ...
- WebWire - HUMIRA is the First Self-Administered Biologic Treatment Offering Sustained Disease Remission in Severe Crohn’s Disease Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA ...
- Chicago Sun-Times - North Chicago-based Abbott Laboratories received authorization from European regulators to market its rheumatoid arthritis drug Humira to treat severe Crohn's disease. Crohn's, an inflammatory disease of the gastrointestinal tract, affects more than ...
- Forbes - ABBOTT PARK, Illinois (Thomson Financial) - Abbott Laboratories Inc said it has received approval from the European Commission to market Humira as treatment for Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract. Copyright ...
- Forbes - Drug and medical products maker Abbott Laboratories said Wednesday the European Commission approved marketing for Humira, a treatment for Crohn's disease. Abbott said Humira is the first self-administered biotech drug for Crohn's disease, a chronic ...
- MSN MoneyCentral - HUMIRA is the First Self-Administered Biologic Treatment Offering Sustained Disease Remission in Severe Crohn's Disease ABBOTT PARK, Ill., June 7 /PRNewswire-FirstCall/ -- Abbott ABT announced today that it has received marketing authorization from ...
- MSN MoneyCentral - HUMIRA is the First Self-Administered Biologic Treatment Offering Sustained Disease Remission in Severe Crohn's Disease ABBOTT PARK, Ill., June 7 /PRNewswire-FirstCall/ -- Abbott ABT announced today that it has received marketing authorization from ...
- Wall Street Journal - Competitors to Humira for certain diseases include Johnson & Johnson's Remicade and the drug Enbrel, which is co-marketed by Amgen Inc. and Wyeth . Also, Belgian pharmaceutical company UCB SA is targeting its drug Cimzia at multiple diseases. Remicade is ...
- CNN Money - Abbott built its new plant to make the blockbuster biotech drug Humira, a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease that contributes heavily to company sales. Humira accounted for $2 billion ...
- Earthtimes - ... Vice President of Global Cardiovascular Marketing and Divisional Vice President and General Manager of Abbott Immunology Under his leadership, he helped Abbott Immunology to successfully obtain approval, launch and commercialization of HUMIRA(R) for ...
- MSN MoneyCentral - ... Vice President of Global Cardiovascular Marketing and Divisional Vice President and General Manager of Abbott Immunology Under his leadership, he helped Abbott Immunology to successfully obtain approval, launch and commercialization of HUMIRA(R ...
- Arlington Heights Daily Herald - NORTH CHICAGO -- Abbott reported Tuesday that results from a follow-up study of 854 adult patients with Crohn's disease taking the drug Humira were 57 percent less likely of being hospitalized than patients taking a placebo after one year. In ...
Want to contact a District of Columbia Humira lawyer? ...Get a free case evaluation from one of our District of Columbia Humira lawyers now.
Pages: 1 2 3 4 5 6 ... Next
